Topics

Immunothrombosis Associated With Neutrophil Extracellular Traps

Chronic Inflammation Intercellular Communication & Diseases Tumor Microenvironment Oxidative Stress

Immunothrombosis is an innate defense program in which immune activation and coagulation cooperate to confine infection, but the same program becomes injurious when it is excessive or fails to resolve. Neutrophil extracellular traps (NETs)-webs of chromatin decorated with granular and cytosolic proteins-capture microbes and coordinate communication among neutrophils, complement, platelets, and vascular cells. In sepsis, antiphospholipid syndrome, acute lung injury, and several neurological disorders, abundant or persistent NETs shift this protective response toward thromboinflammation, microvascular obstruction, endothelial injury, and organ dysfunction. The key biological problem is therefore not whether NETs are beneficial or harmful in absolute terms, but how their timing, location, composition, and clearance determine the balance between antimicrobial containment and pathological thrombosis[1][2][3].

NET-associated immunothrombosis develops through reciprocal activation rather than a single linear pathway. Activated endothelium recruits neutrophils and platelets, while platelet–neutrophil interactions amplify NET release and provide surfaces that support coagulation. NET chromatin acts as a physical scaffold for cellular and plasma components, and NET-associated molecules can intensify inflammation and cytotoxicity. Complement activation, platelet activation, impaired fibrinolysis, and tissue-factor-bearing innate immune cells further stabilize this procoagulant state. In sepsis, these processes concentrate clotting within the microcirculation: initially this can restrict pathogen dissemination, but continued endothelial dysfunction and microthrombus formation compromise tissue perfusion. Similar interactions operate in antiphospholipid syndrome, where autoantibodies, complement, endothelial cells, platelets, myeloid cells, and NETs converge to produce recurrent thrombosis and chronic occlusive vasculopathy. Experimental approaches include degrading the extracellular DNA scaffold with DNase, inhibiting NET formation, limiting platelet–endothelial or platelet–neutrophil activation, and restoring endothelial or complement control[1][2][3][4].

The clinical expression depends on the vascular bed. In acute lung injury, NETs help control pathogens yet expose tissue to pro-inflammatory and cytotoxic cargo that can aggravate alveolar damage and thromboinflammation. At the neurovascular interface, platelet–neutrophil crosstalk and NET-derived damage-associated signals can disrupt brain barriers, facilitate entry of harmful circulating factors, activate inflammasomes, and amplify neuroinflammation. These observations connect venous and arterial thrombosis, sepsis-associated microangiopathy, pulmonary injury, and neurovascular disease through a shared mechanism while also warning against a uniform treatment strategy. Biomarkers that merely detect NET components may not distinguish productive antimicrobial activity from pathogenic accumulation, and circulating measurements may not represent the burden within a specific organ. Therapeutic development is consequently moving from nonspecific neutrophil suppression toward context-dependent modulation. Each strategy carries a safety trade-off because defective NET release or excessive degradation can weaken pathogen control. Assay harmonization across laboratories is necessary before NET measurements can guide enrollment or dosing[1][3][4][5].

Trials therefore need mechanistically defined patients, organ-specific readouts, standardized NET assays, and attention to disease phase. Serial sampling should distinguish formation from impaired clearance, and intervention studies should pair soluble NET markers with imaging, coagulation indices, endothelial measurements, and organ outcomes. Cross-disease comparisons may reveal conserved NET programs, but validation must retain organ context and distinguish infection-driven from sterile thromboinflammation. Future work should determine which NET structures are causative, identify the point at which immunothrombosis becomes maladaptive, and test whether combinations that preserve host defense while improving NET clearance can reduce thrombosis and organ injury more effectively than broad anticoagulation or anti-inflammatory treatment alone[1][3][4].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-17589 Chloroquine phosphate
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
Parasite   Autophagy   SARS-CoV   Toll-like Receptor (TLR)   HIV   Antibiotic  
Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Rheumatoid Arthritis  
1344
HY-17589A Chloroquine
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
Parasite   Autophagy   SARS-CoV   Toll-like Receptor (TLR)   HIV   Antibiotic  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Rheumatoid Arthritis  
1344
HY-16658B Z-VAD-FMK
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
Caspase   Apoptosis   RIP kinase   Glutathione Peroxidase   Reactive Oxygen Species (ROS)  
Cancer   Digestive System Disease   Pancreatitis  
850
HY-D1056 Lipopolysaccharides, from E. coli O55:B5
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Source: surface of Gram-negative bacteria

Toll-like Receptor (TLR)  
Cancer   Pain   Autoimmune Disease   Escherichia Coli Infection  
616
HY-100218A RSL3
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
p62   Glutathione Peroxidase   Ferroptosis   Reactive Oxygen Species (ROS)  
Ovarian Cancer  
573
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-14648C Dexamethasone (Water Soluble)
Dexamethasone (Hexadecadrol) Water Soluble is a water-soluble form of Dexamethasone (HY-14648). Dexamethasone is a glucocorticoid receptor agonist, apoptosis inducer, and a common disease inducer in experimental animals. It can be used to construct models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has the potential to be used in COVID-19 research.(Sale size is the weight of dexamethasone)
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Coronavirus Infection   Depression   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   Hypertension  
402
HY-14648 Dexamethasone
Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research.
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic   ADC Payloads  
Metabolic or Endocrine Disease   Prostate Cancer   Pancreatic Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Autoimmune Disease   Digestive System Inflammation   Cardiovascular Disease   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
402
HY-B0579 Cyclosporin A
Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.

Source: the fungus Beauveria nivea.

Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
214
HY-L001P Bioactive Compound Library Plus
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 32,925 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

General Bioactive Screening Libraries

131
HY-13740 Resiquimod
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
Toll-like Receptor (TLR)   HCV  
Prostate Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   SARS-CoV-2 Infection   Hepatitis C Virus Infection  
120
HY-L022P FDA-Approved Drug Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,663 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

97
HY-W031727 Hydroxychloroquine
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling.
Parasite   Toll-like Receptor (TLR)   SARS-CoV   Autophagy  
Prostate Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   Rheumatoid Arthritis  
95
HY-L021P Natural Product Library Plus
Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. Natural sources may lead to basic research on potential bioactive components for commercial development as lead compounds in drug discovery. Nature has been a source of medicinal agents for thousands of years, and an impressive number of modern drugs have been isolated from natural sources, many based on their use in traditional medicine. With the development of new molecular targets, there is an increasing demand for novel molecular diversity for screening. Natural products will play a crucial role in meeting this demand through the continued investigation of world’s bio-diversity, much of which remains unexplored. MCE provides a unique collection of 6,400 natural compounds that contains Saccharides and Glycosides, Phenylpropanoids, Quinones, Flavonoids, Terpenoids and Glycosides, Steroids, Alkaloid, Phenols, Acids and Aldehydes. Natural Product Library Plus, with more powerful screening capability, further complements Natural Product Library (HY-L021) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Natural Product Screening Libraries

92
HY-L035P Drug Repurposing Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing. MCE Drug Repurposing Compound Library plus contains 6,142 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

Drug Repurposing Series

89
HY-L026P Clinical Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 3,298 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

86
HY-L136 Coagulation and Anti-coagulation Compound Library
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,525 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Signaling Pathway Targeting Libraries

85
HY-L036P Covalent Screening Library Plus
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 6,121 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Structure Classified Libraries

83
HY-L088 Angiogenesis-Related Compound Library
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 3,660 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Signaling Pathway Targeting Libraries

83
HY-L193 PBCRBS Traditional Chinese Medicine Compound Library
Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields. MCE can supply 1,006 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.
83
HY-L207 Mass Spectrometry Human Endogenous Metabolite Library
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms. MCE can provide 661 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Metabolism Focused Libraries

83
HY-135748 Polyinosinic-polycytidylic acid sodium
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   Apoptosis  
Cancer   Digestive System Disease   Pain   Autoimmune Disease   Digestive System Inflammation   Lung Fibrosis  
75
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-112654 GCN2iB
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
Eukaryotic Initiation Factor (eIF)   Glutathione Peroxidase  
Glucose Metabolism   Acute Myeloid Leukemia   Acute Lymphoblastic Leukemia   Cardiomyopathy  
65
HY-B0180 Imiquimod
Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Inflammation or Immune System Disease   Metastatic Breast Cancer   SARS-CoV-2 Infection  
62
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
57
HY-100514 GSK484 hydrochloride
GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.
Protein Arginine Deiminase  
Cancer   Inflammation or Immune System Disease   Cardiovascular Disease  
57
HY-101502A SB290157 trifluoroacetate
SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
Complement System  
Leukemia/Lymphoma/Myeloma   Autoimmune Disease  
36
HY-17443B Sivelestat sodium tetrahydrate
Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
Elastase   SARS-CoV  
Cancer   Viral Infection  
33
HY-17443A Sivelestat sodium
Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
Elastase   SARS-CoV  
Cancer   Viral Infection  
33
HY-17443 Sivelestat
Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
Elastase   SARS-CoV  
Cancer   Viral Infection   SARS-CoV-2 Infection  
33
HY-100003 ML-210
ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.
Glutathione Peroxidase   Ferroptosis  
Ovarian Cancer  
33
HY-B0282 Acetylcholine chloride
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent and BBB-permeable cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs). Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro.
nAChR   Calcium Channel   Endogenous Metabolite  
Breast Cancer   Viral Infection   Alzheimer's Disease  
33
HY-100574A Cl-amidine hydrochloride
Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model.
Protein Arginine Deiminase   Apoptosis   MicroRNA  
Cancer   Digestive System Disease   Digestive System Inflammation  
26
HY-14909 Bardoxolone
Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma.
Keap1-Nrf2   NF-κB   SARS-CoV   Apoptosis   Reactive Oxygen Species (ROS)   Glutathione Peroxidase   Necroptosis  
Inflammation or Immune System Disease   Glioblastoma   SARS-CoV-2 Infection  
25
HY-153808 Complete Freund's adjuvant (CFA)
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
25
HY-N0171A Beta-Sitosterol (purity>98%)
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
Bacterial   Apoptosis   Reactive Oxygen Species (ROS)   MDM-2/p53   Caspase   PARP   MMP   Bcl-2 Family   HIF/HIF Prolyl-Hydroxylase   TNF Receptor   Interleukin Related   NF-κB   mTOR   Lactate Dehydrogenase   CDK   Glutathione Peroxidase   SOD  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
24
HY-100002 ML162
ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
Glutathione Peroxidase   Ferroptosis  
Ovarian Cancer  
18
HY-112005 DOPE
DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.
Liposome   Endogenous Metabolite   ACSL Family   Amino acid Transporter   Ferroptosis   Glutathione Peroxidase  
Cancer   Inflammation or Immune System Disease  
14
HY-127105 Iptacopan
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).
Complement System  
Metabolic or Endocrine Disease   Autoimmune Disease  
13
HY-15651 Alvelestat
Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis.
Elastase   Claudin   Interleukin Related   MMP  
Skin Inflammation   Pulmonary Disease   Aneurysm  
12
HY-15891A GW311616 hydrochloride
GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM.
Elastase  
Inflammation or Immune System Disease  
11
HY-111347 BB-Cl-Amidine
BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.
Protein Arginine Deiminase  
Inflammation or Immune System Disease  
11
HY-P0019A Z-Gly-Gly-Arg-AMC acetate
Z-Gly-Gly-Arg-AMC acetate is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).
Fluorescent Dye   Thrombin  
11
HY-111347A BB-Cl-Amidine hydrochloride
BB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor.
Protein Arginine Deiminase  
Inflammation or Immune System Disease  
11
HY-P0019 Z-Gly-Gly-Arg-AMC
Z-Gly-Gly-Arg-AMC is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).
Fluorescent Dye   Thrombin  
Blood or Cardio-cerebrovascular Disease  
11
HY-D0199 Adenosine 5'-diphosphate disodium
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis.
Endogenous Metabolite  
Cardiovascular Disease  
10
HY-106178 PMX-53
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.
Complement System  
Cancer   Autoimmune Disease   Cardiovascular Disease  
9
HY-139414 Lysophosphatidylcholines
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis.
Interleukin Related   p38 MAPK   ERK   Apoptosis  
Inflammation or Immune System Disease  
7
HY-75957 DMP 777
DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.
Elastase  
Inflammation or Immune System Disease  
6
HY-P2974 Elastase, Porcine pancreas
Elastase, Porcine pancreas (EC 3.4.21.36) is a single polypeptide chain of 240 amino acid residues, derived from pig pancreas. Elastase, Porcine pancreas is a serine protease that can hydrolyze proteins and polypeptide. Elastase from porcine pancreas can induce emphysema in hamsters.
Elastase  
Metabolic or Endocrine Disease  
6
HY-113216 Asymmetric dimethylarginine
Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a number of pathological states.
Endogenous Metabolite   NO Synthase  
Breast Cancer   Viral Infection  
5
HY-N0194 Asiatic acid
Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model.
Apoptosis   Parasite  
Cancer   Digestive System Disease   Parasitic Infection   Depression   Digestive System Inflammation  
5
HY-B0388 Probucol
Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases.
Virus Protease   Apoptosis   Reactive Oxygen Species (ROS)   Glutathione Peroxidase   Caspase  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Viral Infection   Digestive System Inflammation   Glucose Metabolism  
5
HY-17627 Avacopan
Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
Complement System  
Autoimmune Disease  
5
HY-116282 Dextran sulfate sodium salt (MW 5000)
Dextran sulfate sodium salt (DSS) (MW 5000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt (DSS) with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 5000) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 5000) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (DSS) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 5000) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 5000) inhibits instant blood-mediated inflammatory reaction (IBMIR).
HIV   Complement System   Apoptosis  
Infection   Inflammation or Immune System Disease  
5
HY-NP013 Oxidized low density lipoprotein (mouse)
Oxidized low density lipoprotein (mouse) (Mouse ox-LDL) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration. Oxidized low density lipoprotein (mouse) can be used to construct an in vitro model of AS.
LDLR   ROR   β-catenin  
Blood or Cardio-cerebrovascular Disease  
4
HY-P9914 Eculizumab
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies.

Species: Human

Complement System  
CNS Infection   Visual System Disease   Blood Disease   SARS-CoV-2 Infection  
4
HY-19908 BAY-85-8501
BAY-85-8501 is a selective, reversible and potent inhibitor of Human Neutrophil Elastase (HNE), with an IC50 of 65 pM.
Elastase  
Metabolic or Endocrine Disease  
3
HY-101795 Larixyl acetate
Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction.
TRP Channel   HPV   Autophagy   Apoptosis   PERK   Akt   Src  
Infection   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity   Lung Fibrosis  
3
HY-145237 BM213
BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury.
Complement System   Apoptosis   Reactive Oxygen Species (ROS)  
Cancer  
3
HY-P99444 Astegolimab
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research.

Species: Human

Interleukin Related   MDM-2/p53   NF-κB  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
3
HY-P3252AS Pegcetacoplan-13C3,15N TFA
Pegcetacoplan-13C3,15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Isotope-Labeled Compounds   Complement System  
Inflammation or Immune System Disease  
2
HY-121309 Doxorubicinone
Doxorubicinone (Adriamycin aglycone) is the aglycone of the antibiotic Doxorubicin (HY-15142A), i.e., its sugar-free parent nucleus structure. Doxorubicinone does not induce DNA damage or bind to RelA, but still downregulates the expression of pro-inflammatory cytokines (such as TNF, IL-12, etc.) regulated by the NF-κB pathway. Doxorubicinone can be used in sepsis-related research.
NF-κB   TNF Receptor   Interleukin Related   Drug Derivative  
Cancer   Inflammation or Immune System Disease  
2
HY-P4846 Ac-Pro-Gly-Pro-OH
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist. Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer.
CXCR   Apoptosis   IFNAR   TNF Receptor   Interleukin Related  
Infection   Allergy  
2
HY-N1990 Gypenoside XLIX
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
PPAR   Sirtuin   Keap1-Nrf2   Toll-like Receptor (TLR)   NF-κB   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   Apoptosis   Pyroptosis   Autophagy  
Neurological, Eye or Ear Disease   Atherosclerosis and Inflammation   Acute Lung Injury   Cardiomyopathy   Liver Injury  
2
HY-P990131 Anti-Mouse CD47/IAP Antibody (MIAP301)
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis.

Species: Mouse

CD47  
Melanoma   Klebsiella Pneumoniae Infection   Sepsis  
2
HY-124586 Streptonigrin
Streptonigrin (Bruneomycin) is an orally active antibiotic and pan-PAD inhibitor, inhibiting PAD1, PAD2, PAD3 and PAD4 with IC50 of 48.3 μM, 26.1 μM, 0.43 μM and 2.5 μM, respectively. Streptonigrin inhibits SENP1 (IC50 of 0.518 μM) and reduces HIF1α. Streptonigrin increases p53 and Apoptosis. Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma.

Source: Streptomyces flocculus

Antibiotic   Protein Arginine Deiminase   E1/E2/E3 Enzyme   HIF/HIF Prolyl-Hydroxylase   MDM-2/p53   Apoptosis  
Infection   Inflammation or Immune System Disease  
2
HY-P99008 Atibuclimab
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury.

Species: Human

Toll-like Receptor (TLR)  
Inflammation or Immune System Disease   Pulmonary Disease   SARS-CoV-2 Infection   Amyotrophic Lateral Sclerosis  
2
HY-N6018 β-Eudesmol
β-Eudesmol has anticancer and anti-inflammatory activities. Beta-Eudesmol can induce apoptosis. β-Eudesmol is a neostigmine antagonist. β-Eudesmol can antagonize neostigmine-induced neuromuscular failure. β-Eudesmoll can be used in the study of sepsis diseases. β-Eudesmol is a sesquiterpene-like compound that can be extracted from the rhizome of Atractylodes lancea.
Caspase   TNF Receptor   SOD   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease  
2
HY-N0353 Curdione
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
Ferroptosis   Apoptosis   Reactive Oxygen Species (ROS)   Autophagy   Glutathione Peroxidase   Keap1-Nrf2   Heme Oxygenase (HO)   TGF-β Receptor   Indoleamine 2,3-Dioxygenase (IDO)  
Colorectal Cancer   Pancreatic Cancer   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Lung Fibrosis  
2
HY-103058 GSK199
GSK199 is an orally active, reversible, and selective PAD4 inhibitor with an IC50 of 200 nM in the absence of calcium. GSK199 can be used for the research of rheumatoid arthritis.
Protein Arginine Deiminase  
Cancer   Cardiovascular Disease   Rheumatoid Arthritis  
2
HY-136557A AFM32a hydrochloride
AFM32a (PAD2-IN-1) hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).
Protein Arginine Deiminase  
Cancer   Inflammation or Immune System Disease  
2
HY-P9934 Abciximab
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.

Species: Human

Integrin  
Blood or Cardio-cerebrovascular Disease  
2
HY-P99644 ACT017
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.

Species: Human

Glycoprotein VI  
Blood or Cardio-cerebrovascular Disease  
2
HY-N9481 Lipoteichoic acid
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin.

Source: Staphylococcus aureus

Complement System   Autophagy   mTOR   Akt   PI3K   ERK   Interleukin Related  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-P99227 Caplacizumab (His Tag)
Caplacizumab (His Tag) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab (His Tag) inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab (His Tag) inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab (His Tag) can be used for the research of thrombotic thrombocytopenic purpura (TTP).

Species: Human

Integrin   Transmembrane Glycoprotein  
Blood or Cardio-cerebrovascular Disease  
2
HY-13679 Sodium 2-mercaptoethanesulfonate
Mesna (Sodium 2-mercaptoethanesulfonate) is an antioxidant which has cytoprotective effects. Mesna is widely used as a systemic protective agent against chemotherapy toxicity. Mesna is also used to reduce hemorrhagic cystitis induced by cyclophosphamide.
Glutathione Peroxidase  
Cancer  
2
HY-P3252A Pegcetacoplan acetate
Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Complement System  
Inflammation or Immune System Disease  
2
HY-P10208 RKH
PKH is a TLR4 antagonist. PKH is a novel tripeptide and can be isolated from Akkermansia muciniphila. RKH reduces sepsis-induced inflammatory cell activation and proinflammatory factor overproduction.
Toll-like Receptor (TLR)  
Infection  
1
HY-P99753 Nerelimomab
Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis.

Species: Human

TNF Receptor  
Infection  
1
HY-P1505 C3a (70-77)
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
Complement System  
Inflammation or Immune System Disease  
1
HY-112234 L-Sepiapterin
L-Sepiapterin (Sepiapterin), is a phenylalanine hydroxylase activator, is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression. L-Sepiapterin can be used for the study of hyperphenylalaninemia.
Endogenous Metabolite  
Cancer  
1
HY-P99121 Anti-Mouse/Human CD11b Antibody (M1/70)
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer.

Species: Mouse

Integrin  
Cancer   Inflammation or Immune System Disease  
1
HY-110398 5,6,7-Trimethoxyflavone
5,6,7-Trimethoxyflavone is a flavonoid compound that can be isolated from plants Callicarpa japonica. 5,6,7-Trimethoxyflavone exhibits antiviral and anti-inflammatory activities through inhibition of NF-κB/AP-1/STAT signaling pathway.
NF-κB   AP-1   STAT   HSV   CMV   Enterovirus  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity  
1
HY-P1505A C3a (70-77) TFA
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
Complement System  
Inflammation or Immune System Disease  
1
HY-P10208A RKH acetate
RKH acetate exerts protective effects against sepsis-induced death and organ damage. RKH acetate can directly bind to Toll-like receptor 4 (TLR4) and block TLR4 signal transduction in immune cells.
Toll-like Receptor (TLR)  
Infection   Inflammation or Immune System Disease  
1
HY-129997 Luteolinidin chloride
Luteolinidin chloride is a deoxyanthocyanidin isolated from the plant Sorghum bicolor with antioxidant activity. Luteolinidin chloride is a potent CD38 inhibitor (Ki=11.4 μM) and protects the heart from ischemia/reperfusion injury by preserving endothelial nitric oxide synthase (eNOS) function and preventing endothelial dysfunction. Luteolinidin chloride is also a competitive inhibitor of tyrosinase (IC50=3.7 μM) and blocks the production of melanin.
CD38   NADPH Oxidase   Tyrosinase  
Inflammation or Immune System Disease   Cardiovascular Disease   Lung Fibrosis  
1
HY-W329357 15:0 Lyso PC
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
Endogenous Metabolite  
Cardiovascular Disease  
1
HY-108052 Delphinidin 3-glucoside chloride
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL). Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM. Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM. Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction.
EGFR   Apoptosis   Akt  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Cardiovascular Disease   Hepatitis C Virus Infection   Parkinson's Disease   Obesity   Lung Fibrosis  
1
HY-N2393 Kukoamine B
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis.
Apoptosis   MMP   MAPKAPK2 (MK2)   p38 MAPK   PI3K   Akt   Reactive Oxygen Species (ROS)   DNA/RNA Synthesis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
1
HY-N0563 Alizarin
Alizarin is a natural dye. Alizarin can be extracted from the roots of madder plant. Alizarin activates AMPK and VEGFR2/eNOS pathway. Alizarin regulates PI3K/Akt and inhibits NF-κB pathway. Alizarin enhances CYP1A1 enzyme activity. Alizarin has protective effects on hypertension and vascular endothelial dysfunction. Alizarin has anti-tumor activity against multiple cancers including pancreatic cancer, breast cancer, osteosarcoma and liver cancer. Alizarin has been widely used as a pigment in textile fabrics and paintings.
AMPK   VEGFR   PI3K   Akt   NF-κB   Cytochrome P450  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Hypertension   Obesity  
1
HY-125099A AFM-30a hydrochloride
AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.
Protein Arginine Deiminase  
Cancer   Rheumatoid Arthritis  
1
HY-P10368 P110 heptapeptide
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases.
Dynamin   Reactive Oxygen Species (ROS)  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
1
HY-D1056B3 Lipopolysaccharides, from Klebsiella pneumoniae
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct Acute Lung Injury Model.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-P81185 C5b-9 Antibody
C5b-9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to C5b-9.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Primary Antibodies

1
HY-15371G Forskolin (GMP)
Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin (GMP) is also an inducer of intracellular cAMP formation. Forskolin (GMP) induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy.
Adenylate Cyclase   FXR   Autophagy   PKC  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P11791 nNIF peptide
nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis.
Endogenous Metabolite  
Coronavirus Infection  
/
HY-126967AS 1-Palmitoyl-sn-glycerol 3-phosphate-d9
1-Palmitoyl-sn-glycerol 3-phosphate-d9 (1-P-GPA-d9) is the d9 labeled 1-Palmitoyl-sn-glycerol 3-phosphate (HY-126967A). 1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is a phospholipid and lipid membrane precursor. 1-Palmitoyl-sn-glycerol 3-phosphate integrates into POPC liposomes, causing significant changes in membrane curvature. 1-Palmitoyl-sn-glycerol 3-phosphate induces platelet aggregation, but its activity is 30-fold lower than that of 1-hexadecyl-sn-glyceryl-3-phosphate.
Isotope-Labeled Compounds   Liposome  
Platelet Disease  
/
HY-P10274 CM05
CM05 is a bromo-fatty acid. CM05 can be used to modify ornithodoros moubata complement inhibitor (OmCI) and extend the half-life of OmCI.
Complement System  
Inflammation or Immune System Disease  
/
HY-N0353R Curdione (Standard)
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
Reference Standards   Ferroptosis   Apoptosis   Reactive Oxygen Species (ROS)   Autophagy   Glutathione Peroxidase   Keap1-Nrf2   Heme Oxygenase (HO)   TGF-β Receptor   Indoleamine 2,3-Dioxygenase (IDO)  
Cancer  
/
HY-P5528 2Abz-SLGRKIQIK(Dnp)-NH2
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)
Others  
/
HY-N1208 Spiradine F
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activating factor (PAF)-induced platelet aggregation.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10868A Pegtarazimod TFA
Pegtarazimod TFA (RLS-0071 TFA) is a dual-target anti-inflammatory peptide that exerts its effects by simultaneously regulating the complement system and neutrophil-associated inflammatory pathways. Pegtarazimod TFA reduces ROS production both in vitro and in vivo, and decreases the level of neutrophil elastase, a marker of neutrophil extracellular traps (NETs), in vivo, thereby alleviating inflammatory responses. Pegtarazimod TFA significantly improves the survival rate of mice in multiple in vivo models of acute graft-versus-host disease (aGVHD). Pegtarazimod TFA inhibits the activation of the C1 complex, reduces the herpes zoster-like spread of herpes simplex virus type 1 skin infection, and improves the survival rate of infected mice. Pegtarazimod TFA can be used in research related to acute graft-versus-host disease, acute pulmonary diseases, and skin herpes simplex virus type 1 infection.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   HSV Infection  
/
HY-17627S1 Avacopan-d4
Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
Isotope-Labeled Compounds   Complement System  
Inflammation or Immune System Disease  
/
HY-NP216 PA-IIL
PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection.
Integrin   Endogenous Metabolite   Bacterial  
Pseudomonas Aeruginosa Infection  
/
HY-18763S Indobufen-d5
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
Isotope-Labeled Compounds   COX  
Blood or Cardio-cerebrovascular Disease  
/
HY-NP0194B C1q Protein (rabbit)
C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-P1184 HNGF6A
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.
Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-15284S3 Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
Isotope-Labeled Compounds   P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-100607S Landiolol-d8
Landiolol-d8 (ONO1101-d8) is the deuterium labeled Landiolol (HY-100607). Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
Isotope-Labeled Compounds   Potassium Channel   Adrenergic Receptor   Calcium Channel   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P991701 Mebarase alfa
Mebarase alfa is a human monoclonal antibody targeting ENTPD1/CD39 for the study of sepsis-associated renal injury.

Species: Human

NTPDase  
Cancer  
/
HY-W744578 Taurolidine-d6
Taurolidine-d6 is the deuterium labeled Taurolidine (HY-W011522). Taurolidine is a potent antimicrobial and anticancer agent. Taurolidine inhibits cell proliferation. Taurolidine induces apoptosis and autophagy. Taurolidine rescues mice from sepsis-associated lethality.
Isotope-Labeled Compounds   Autophagy   Bacterial   Apoptosis   Antibiotic  
Cancer  
/
HY-P11868 PADI4_3
PADI4_3 is a substrate-competitive and selective PADI4 inhibitor with an IC50 of 56 nM. PADI4_3 blocks citrullination of histone H3 and reduces the formation of neutrophil extracellular traps. PADI4_3 can be used in research related to autoimmune diseases and cancers.
Protein Arginine Deiminase  
Cancer   Autoimmune Disease  
/
HY-N7955 23-O-Acetylcimigenol-3-O-α-L-arabinopyranside
23-O-Acetylcimigenol-3-O-α-L-arabinopyranside (Compound 1) is a triterpene glycoside found in the rhizomes of Cimicifuga heracleifolia.23-O-Acetylcimigenol-3-O-α-L-arabinopyranside does not inhibit the classical pathway of the complement system.
Others  
/
HY-N19128 Pulchinenoside J
Pulchinenoside J is a lupane-type triterpenoid saponin and a complement system inhibitor that acts via the classical pathway. Pulchinenoside J can be isolated from the roots of Pulsatilla chinensis.
Complement System  
/
HY-173418 Carbaprostacyclin-biotin
Carbaprostacyclin-biotin (cPGI-biotin; Carbacyclin-biotin) is a biotin-bound Carbacyclin (Carbaprostacyclin) (HY-112322). Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
Prostaglandin Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-187266S [U-15N]-PCT
[U-15N]-PCT is the 15N-labeled PCT. Procalcitonin (PCT) is a highly specific marker reflecting the severity of inflammation and a key indicator of sepsis. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Inflammation or Immune System Disease  
/
HY-182607 SA buffer, 1×, pH 7.4
SA buffer, 1×, pH 7.4, is mainly composed of sodium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, etc. It is the most commonly used reagent for diluting serum and other samples in immunotoxicology experiments, and is used for complement determination experiments, etc.
Biochemical Assay Reagents  
/
HY-P99815 Pegacaristim
Pegacaristim is a monoclonal antibody with thrombopoietic activity. Pegacaristim can promote generation of platelets.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P3052 RGDV
RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect.
Others  
/
HY-D1056C4 Lipopolysaccharides, from S. enterica serotype abortus equi
Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype Abortusequi are lipopolysaccharide endotoxins and TLR-4 activators derived from the Abortusequi serotype of S. enterica, classified as a mutated R-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype abortus equi consist of core oligosaccharide (core oligosaccharide) and lipid A (Lipid A). S. enterica serotype Abortusequi is a major pathogen causing abortion in mares and is also associated with neonatal sepsis, multiple abscesses, orchitis, and polyarthritis in equids. It is primarily grouped based on lipopolysaccharides (O-antigen) and flagellin (H-antigen).
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P3531 Fibrinogen γ-chain (397-411)
Fibrinogen γ-chain (397-411), a esidues 397-411 of the γ chain of fibrinogen, is a site recognizing the platelet receptor, which is distinct from the site(s) involved in polymerization of fibrin monomers.
Others  
/
HY-N20312 Lonicerae flos extract
Lonicerae flos extract is an extract of Lonicera japonica that can be used in research on sepsis.
Others  
Inflammation or Immune System Disease  
/
HY-N8706 Hydrangetin
Hydrangetin inhibits platelet aggregation. Hydrangetin can be isolated from Zanthoxylum schinifolium.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-N12265 Versicolactone B
Versicolactone B is a sesquiterpene that can be isolated from Viola yedoensis. Versicolactone B exhibits anti-complement activity against the classical pathway and the alternative pathway.
Others  
Inflammation or Immune System Disease  
/
HY-113216S Asymmetric dimethylarginine-d7 hydrochloride hydrate
Asymmetric dimethylarginine-d7 (hydrochloride hydrate) is the deuterium labeled Asymmetric dimethylarginine. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a num
Isotope-Labeled Compounds   Endogenous Metabolite   NO Synthase  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-127063 Pseudojervine
Pseudojervine is a glycoalkaloid with a feeble inhibition activity against platelet aggregation.
Others  
Neurological, Eye or Ear Disease  
/
HY-158485 M5 glycan (Man5)
M5 glycan (Man5) (Mannose-5 N-linked oligosaccharide; Oligomannose 5 glycan) is an N-linked glycan on glycoproteins on glycoproteins. M5 glycan (Man5) enhances antibody-dependent cell-mediated cytotoxicity and reduces complement-dependent cytotoxicity.
Biochemical Assay Reagents  
/
HY-N2393S Kukoamine B-d5 dihydrochloride
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .
MMP   Apoptosis   MAPKAPK2 (MK2)   p38 MAPK   PI3K   Akt   ROS Kinase   DNA/RNA Synthesis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P991998 Anti-Human/Monkey CD16a Antibody (3G8)
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology.

Species: Human/Monkey

Fc Receptor (FcR)  
Cancer   Inflammation or Immune System Disease  
/
HY-P11384 D-RGDW
D-RGDW is an Arg-Gly-Asp (RGD) containing peptide. D-RGDW inhibits αIIbβ3 mediated platelet aggregation.
Integrin  
Platelet Disease  
/
HY-15284S2 Prasugrel-d4
Prasugrel-d4 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P5991 K-Casein (106-116),bovine
K-Casein (106-116),bovine is an antithrombotic agent and platelet inhibitor. K-Casein (106-116),bovine binds to platelet αIIbβ3 integrin, thereby preventing fibrinogen binding. K-Casein (106-116),bovine inhibits ADP (HY-W010918)-induced platelet aggregation. K-Casein (106-116),bovine can be used in thrombosis-related research.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P992212 Anti-CD62L Antibody (DREG-200)
Anti-CD62L Antibody (DREG-200) is a human monoclonal antibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).

Species: Human

L-Selectin  
Ischemia-Reperfusion Injury  
/
HY-N21519 8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon
8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon is a phenalenone derivative found in the aerial parts of Helicteres angustifolia. 8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon exhibits moderate anti-complement activity against the classical pathway and weak activity against the alternative pathway.
Complement System  
Inflammation or Immune System Disease  
/
HY-W250153A Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
P2Y Receptor  
Platelet Disease  
/
HY-15284S Prasugrel-d5
Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
Isotope-Labeled Compounds   P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991659 SCH708980
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research.

Species: Human

Interleukin Related  
Infection   Inflammation or Immune System Disease  
/
HY-P5949 AMPR-22
AMPR-22 is an antimicrobial peptide. AMPR-22 can bind to the bacterial membrane and induces membrane permeabilization. AMPR-22 is effective against murine model of sepsis induced by MDR strains
Bacterial  
Infection  
/
HY-P1702 GR83895
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM).
Integrin  
/
HY-P10868 Pegtarazimod
Pegtarazimod (RLS-0071) is a dual-target anti-inflammatory peptide that exerts its effects by simultaneously regulating the complement system and neutrophil-associated inflammatory pathways. Pegtarazimod reduces ROS production both in vitro and in vivo, and decreases the level of neutrophil elastase, a marker of neutrophil extracellular traps (NETs), in vivo, thereby alleviating inflammatory responses. Pegtarazimod significantly improves the survival rate of mice in multiple in vivo models of acute graft-versus-host disease (aGVHD). Pegtarazimod inhibits the activation of the C1 complex, reduces the herpes zoster-like spread of herpes simplex virus type 1 skin infection, and improves the survival rate of infected mice. Pegtarazimod can be used in research related to acute graft-versus-host disease, acute pulmonary diseases, and skin herpes simplex virus type 1 infection.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   HSV Infection  
/
HY-P991050 Procizumab
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Dipeptidyl Peptidase  
Inflammation or Immune System Disease  
/
HY-W049802 N-((Allyloxy)carbonyl)-N-methyl-L-alanine
N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-125053 Batifiban
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes.
Integrin  
Blood or Cardio-cerebrovascular Disease  
/
HY-167686 Variabilin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg.
Integrin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P1184A HNGF6A TFA
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-107080 RPR-109891
RPR-109891 is an orally active glycoprotein IIb/IIIa peptide antagonist. RPR-109891 can decrease platelet count and reduce platelet survival time. RPR-109891 can be used for the research of cardiovascular disease, such as myocardial infarction.
Integrin  
Blood or Cardio-cerebrovascular Disease  
/
HY-106102 [Deglycinamide9, Arginine8]-Vasopressin
[Deglycinamide9, Arginine8]-Vasopressin is a Vasopressin (HY-B1811) analog. [Deglycinamide9, Arginine8]-Vasopressin induces platelet aggregation. [Deglycinamide9, Arginine8]-Vasopressin has hemostatic effect.
Endogenous Metabolite  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991657 MEDI7814
MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury.

Species: Human

Complement System  
Blood or Cardio-cerebrovascular Disease  
/
HY-15651S Alvelestat-13C,d3
Alvelestat-13C,d3 (AZD9668-13C,d3) is the deuterated, 13C-labeled Alvelestat (HY-15651). Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis.
Isotope-Labeled Compounds   Elastase   Claudin   Interleukin Related   MMP  
Skin Inflammation   Pulmonary Disease   Aneurysm  
/
HY-B0331S1 Enalapril-d3
Enalapril-d3 (MK-421-d3) is the deuterated-labeled Enalapril (HY-B0331). Enalapril is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)   Apoptosis   Reactive Oxygen Species (ROS)  
Cerebrovascular Disease   Glucose Metabolism   Alzheimer's Disease   Hypertension   Myocardial Infarction   Heart Failure   Atrial Fibrillation  
/
HY-N12189 3β-(Acetyloxy)stigmast-5-en-7-one
3β-(Acetyloxy)stigmast-5-en-7-one has anti-complement activity.
Others  
/
HY-158741 IPG-2 AM
IPG-2 AM (APG-2 Acetoxymethyl ester) is a membrane-permeant acetoxymethyl ester derivative and selective fluorescent potassium ion indicator. IPG-2 AM exhibits fluorescence increases proportional to extracellular potassium ion concentrations. IPG-2 AM enables real-time monitoring of cytosolic free potassium ion fluxes in human platelets and macrophages. IPG-2 AM can be used for the research of intracellular potassium concentration dynamics.
Fluorescent Dye   Potassium Channel  
/
HY-N7314 Asebogenin
Asebogenin has antimalarial activity in vitro. Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps.
Syk  
Inflammation or Immune System Disease  
/
HY-10234S Saracatinib-d3
Saracatinib-d3 (AZD0530-d3) (ZG5129) is the deuterium-labeled analog of Saracatinib (HY-10234). Saracatinib-d3 is an inhibitor of the Src kinase, which can inhibit severe sepsis caused by bacterial or various microbial infections.
Src  
Infection  
/
HY-P992152 Vatreptacog alfa
Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia.

Species: Human

Factor VIIa   Drug Derivative  
Blood Disease  
/
HY-D2466 Cy3 Dextran (MW 70000)
Cy3 Dextran (MW 70000) is a fluorescent labeling reagent that conjugates the Cy3 (HY-D0822) fluorescent dye with Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Dextran inhibits platelet aggregation and coagulation factors, and serves as a plasma volume expander.
Fluorescent Dye  
Blood or Cardio-cerebrovascular Disease  
/
HY-W250153 Adenosine 3'-phosphate 5'-phosphosulfate lithium
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
P2Y Receptor  
Platelet Disease  
/
HY-126042S4 (±)-Lisofylline-d4
(±)-Lisofylline-d4 ((±)-Lisophylline-d4) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research.
Isotope-Labeled Compounds   Interleukin Related  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P3199 PKCβII Peptide Inhibitor I
PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction.
PKC  
Inflammation or Immune System Disease  
/
HY-139133 L-NASPA
L-NASPA is a ophosphatidic acid (LPA) inhibitor useful in the study of platelet activation.
LPL Receptor  
Inflammation or Immune System Disease  
/
HY-W777681 Triflusal-13C6
Triflusal-13C6 is a C13-labeled Triflusal. Triflusal is a platelet aggregation inhibitor.
Isotope-Labeled Compounds  
/
HY-P991029 Sutacimig
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia.

Species: Human

Thrombin   Ser/Thr Protease   TREM receptor  
Platelet Disease  
/
HY-N6580 Ginsenoside Rg4
Ginsenoside Rg4 is an orally active protopanaxatriol type ginsenoside. Ginsenoside Rg4 can activate PI3K, AKT and GSK-3β signaling. Ginsenoside Rg4 can inhibit ROS and inflammatory cytokine levels. Ginsenoside Rg4 can be used for the researches of inflammation, infection and metabolic disease, such as sepsis and lung inflammation.
PI3K   Akt   GSK-3   Reactive Oxygen Species (ROS)   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-125053A Batifiban TFA
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
Glycoprotein VI  
Blood or Cardio-cerebrovascular Disease  
/
HY-B0926B Diatrizoate meglumine
Diatrizoate meglumine (N-Methyl-D-glucamine diatrizoate) is an orally active, water-soluble, poorly absorbable iodinated contrast agent. Diatrizoate meglumine is widely used as an adjuvant for radiological diagnosis and can also be applied to studies of small bowel obstruction in non-malignant conditions.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-W012480S1 DL-Tryptophan-d8
DL-Tryptophan-d8 is the deuterium labeled DL-Tryptophan. DL-Tryptophan ((±)-Tryptophan) is an orally effective aryl hydrocarbon receptor (AhR) agonist. DL-Tryptophan reduces the expression of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, as well as liver injury markers aspartate aminotransferase and alanine aminotransferase, and alleviates hepatocyte apoptosis (apoptosis) in sepsis induced by cecal ligation and puncture. DL-Tryptophan can be used in the research of sepsis-related acute liver injury.
Isotope-Labeled Compounds   Endogenous Metabolite   Aryl Hydrocarbon Receptor   Interleukin Related   TNF Receptor   Apoptosis  
Metabolic or Endocrine Disease  
/
HY-15284S1 Prasugrel-d3
Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-N2996 Ganodermanondiol
Ganodermanondiol is a melanogenesis inhibitor isolated from the Ganoderma lucidum.Ganodermanondiol exhibits potent cytoprotective effects on tert-butyl hydroperoxide-induced hepatotoxicity. Ganodermanondiol shows significant anti-HIV-1 protease activity with an IC50 of 90 μM. Ganodermanondiol exhibits a strong anticomplement activity against the classical pathway of the complement system with an IC50 of 41.7μM.
HIV Protease  
Infection  
/
HY-N7401 Entadamide-A-β-D-glucopyranoside
Entadamide-A-β-D-glucopyranoside is one of the major components in the seeds of Entada phaseoloides. Entadamide-A-β-D-glucopyranoside has anti-complement activitie.
Complement System  
Autoimmune Disease  
/
HY-N8218 Homoeriodictyol 7-O-β-D-glucoside
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activating factor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC50 of 0.8 μM.
Platelet-activating Factor Receptor (PAFR)  
Blood or Cardio-cerebrovascular Disease  
/
HY-B0228S12 Adenosine-d13
Adenosine-d13 (Adenine riboside-d13; D-Adenosine-d13) is deuterium labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Autophagy   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-NP070 Lotus tetragonolobus lectin
Lotus tetragonolobus lectin (LTL) is a plant lectin that specifically recognizes and binds to α-L-fucopyranosyl residues, a sugar structure serving as the key terminal glycosyl group of human blood type O antigen (H antigen). Lotus tetragonolobus lectin exerts macrophage migration inhibitory activity in monomeric form. Lotus tetragonolobus lectin labels and identifies renal proximal tubular epithelial cells to evaluate histopathological changes of sepsis-induced acute kidney injury. Lotus tetragonolobus lectin is applicable to studies in glycobiology, immunology and renal pathology.
/
HY-N12514 Cyclomulberrin
Cyclomulberrin is a extended flavonoid that shows inhibition of arachidonic acid (AA)- and collagen-induced platelet aggregation, with IC50 value of 128.2 μM.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P990378 Anti-Complement Factor P/Properdin Antibody
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P4641 H-Trp-Phe-OH
H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis.
Angiotensin-converting Enzyme (ACE)   Endothelin Receptor  
Hypertension  
/
HY-106279 EA-230
EA-230 is a synthetic oligopeptide originally derived from beta-human chorionic gonadotropin (beta-hCG) lysates. EA-230 has anti-inflammatory effects and can be used for the research of sepsis.
GnRH Receptor  
Inflammation or Immune System Disease  
/
HY-N7097 Sulbenicillin disodium
Sulbenicillin disodium is a semisynthetic α-sulfonylbenzylpenicillin antibiotic. Sulbenicillin disodium exerts antibacterial activity against multiple gram-negative rods. Sulbenicillin disodium inhibits primary and secondary platelet aggregation, serotonin release from platelets, and platelet adherence via platelet surface coating. Sulbenicillin disodium can be used for the research of Pseudomonas aeruginosa, Pseudomonas maltophilia, and Pseudomonas cepacia infections.
Antibiotic   Bacterial  
Pseudomonas Aeruginosa Infection  
/
HY-121636S Resolvin D2-d5
Resolvin D2-d5 is the deuterium labeled Resolvin D2. Resolvin D2 is a metabolite of docosahexaenoic acid (DHA), with anti-inflammatory, anti-infective activities. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Resolvin D2 is a remarkably potent inhibitor of TRPV1 (IC50 = 0.1 nM) and TRPA1 (IC50 = 2 nM) in primary sensory neurons.
TRP Channel  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-NP0194C C1q Protein (rat)
C1q Protein (rat) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rat) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-P99425 Afelimomab
Afelimomab (MAK 195F) is an anti-tumor necrosis factor monoclonal antibody. Afelimomab can be used for the research of sepsis.

Species: Human

TNF Receptor  
Infection   Inflammation or Immune System Disease  
/
HY-P991401 GSK2862277
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P990158 Anti-Mouse Ter-119 Antibody (TER-119)
Anti-Mouse Ter-119 Antibody (TER-119) is an anti-mouse Ter-119 IgG2b monoclonal antibody. Anti-Mouse Ter-119 Antibody (TER-119) can increase platelet count. Anti-Mouse Ter-119 Antibody (TER-119) can remove red blood cells and their precursor cells to isolate and enrich natural killer (NK) cells. Anti-Mouse Ter-119 Antibody (TER-119) can be used for research on immune thrombocytopenia. Anti-Mouse Ter-119 Antibody (TER-119) can be used to construct a model of immune thrombocytopenic purpura combined with CD41 mAb.

Species: Mouse

Others  
Inflammation or Immune System Disease  
/
HY-113248S 3-Nitro-L-tyrosine-d3
3-Nitro-L-tyrosine-d3 is the deuterium labeled 3-Nitro-L-tyrosine (HY-113248). 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
Endogenous Metabolite  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-111247 Ro 09-0680
Ro 09-0680 is a potent inhibitor of rabbit platelet aggregation induced by Collagen with an IC50 of 6.6 μM.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P99298 Lampalizumab
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-151537 Gol-NTR
Gol-NTR is a Golgi-targetable probe with high selectivity and sensitivity. Gol-NTR is Nitroreductase (NTR)-activated and has visualization acute lung injury (ALI) and repair function. Gol-NTR has a low detection limit of 54.8 ng/mL. Gol-NTR can be used for the research for monitoring and assessing research response of sepsis-induced ALI.
Fluorescent Dye  
Infection   Inflammation or Immune System Disease  
/
HY-W047191 D-Glucono-1,4-lactone
D-Glucono-1,4-lactone is a derivative of D-gluconic acid (HY-Y0569C). D-Glucono-1,4-lactone can be isolated from fruits, vegetables, honey, kombucha and wine. D-Glucono-1,4-lactone inhibits thrombin-induced arachidonic acid peroxidation and platelet activation. D-Glucono-1,4-lactone reduces superoxide anion production in thrombin-activated platelets. D-Glucono-1,4-lactone exerts antioxidant activity on platelets under oxidative stress conditions and prevents excessive platelet activation through antioxidant mechanisms. D-Glucono-1,4-lactone can be used in research related to cardiovascular diseases.
Drug Derivative  
Platelet Disease  
/
HY-P11077 LR-17
LR-17 (TLT-1 (94-110)), a 17-aa peptide, is a TREM-1 inhibitor. LR-17 shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LR-17 can be used for the study of sepsis.
TREM receptor  
Inflammation or Immune System Disease  
/
HY-N2163 Mudanpioside C
Mudanpioside C is a protein disulfide isomerase (PDI) inhibitor with a human IC50 of 3.31 μM and human Kd of 3.9 μM. Mudanpioside C suppresses collagen-induced platelet aggregation, interferes with platelet activation, adhesion, and spreading. Mudanpioside C can be used for the research of cardiovascular diseases.
PDI  
Cardiovascular Disease  
/
HY-D0199R Adenosine 5'-diphosphate disodium (Standard)
Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis.
Endogenous Metabolite   Reference Standards  
Blood or Cardio-cerebrovascular Disease  
/
HY-148748G Butyzamide (GMP)
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay.
JAK   STAT   p38 MAPK  
Blood or Cardio-cerebrovascular Disease  
/
HY-W012480S DL-Tryptophan-d3
DL-Tryptophan-d3 is the deuterium labeled DL-Tryptophan. DL-Tryptophan ((±)-Tryptophan) is an orally effective aryl hydrocarbon receptor (AhR) agonist. DL-Tryptophan reduces the expression of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, as well as liver injury markers aspartate aminotransferase and alanine aminotransferase, and alleviates hepatocyte apoptosis (apoptosis) in sepsis induced by cecal ligation and puncture. DL-Tryptophan can be used in the research of sepsis-related acute liver injury.
Isotope-Labeled Compounds   Endogenous Metabolite   Aryl Hydrocarbon Receptor   Interleukin Related   TNF Receptor   Apoptosis  
Metabolic or Endocrine Disease  
/
HY-P10918 F11R peptide TFA
F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelial cells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease.
Others  
Inflammation or Immune System Disease  
/
HY-N1717 2-Acetylbenzoic acid
2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak platelet aggregation inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation.
Platelet-activating Factor Receptor (PAFR)  
Cardiovascular Disease  
/
HY-P99309 Pagibaximab
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis.

Species: Human

Bacterial  
Staphylococcus Aureus Infection  
/
HY-P2310A Defensin HNP-1 human TFA
Defensin HNP-1 human TFA is a type of human neutrophil peptide (HNPs). Defensin HNP-1 human TFA possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human TFA inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human TFA has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human TFA has antileishmanial activity. Defensin HNP-1 human TFA is involved in endothelial cell dysfunction during the early development of atherosclerosis.
Bacterial   Parasite   Apoptosis   HIV   HSV   CMV   TNF Receptor   Interleukin Related   NOD-like Receptor (NLR)   DNA/RNA Synthesis   Influenza Virus  
Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-N0194R Asiatic acid (Standard)
Asiatic acid (Standard) is the analytical standard of Asiatic acid. This product is intended for research and analytical applications. Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model.
Reference Standards   Apoptosis   Parasite  
Cancer   Inflammation or Immune System Disease  
/
HY-112486G TA-316 (GMP)
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist.
Cyclin G-associated Kinase (GAK)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10827 PIC1 PA
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM.
Complement System  
Inflammation or Immune System Disease  
/
HY-P4344 Met-Gly-Pro-AMC
Met-Gly-Pro-AMC is a fluorescent peptide substrate active against *Caenorhabditis elegans* DPF-3, hDPP4, and methionyl aminopeptidase 2 (MetAP2). Met-Gly-Pro-AMC undergoes cleavage via tripeptidyl peptidase activity to release a fluorescent product. Met-Gly-Pro-AMC is used to detect the activities of tripeptidyl peptidases and MetAP2 peptidases in in vitro enzyme activity assays.
MetAP   Dipeptidyl Peptidase   Fluorescent Dye  
Obesity  
/
HY-P99358 Dezamizumab
Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P10827A PIC1 PA TFA
PIC1 PA TFA is the trifluoroacetate salt form of PIC1 PA (HY-P10827). PIC1 PA TFA is a 15-amino acid peptide that is a potent PIC1 analog that inhibits classical complement activation.
Complement System  
Inflammation or Immune System Disease  
/
HY-N1464A Aristolone
Aristolone is a sesquiterpene that can be isolated from Aristolochia debilis, Rosmarinus officinalis and Ficus Auriculata. Aristolone in Ara Fruit can be used as a prediction of apoptosis in HeLa cells. Aristolone inhibits the C1 complement component. Aristolone produces cytotoxicity effects on cells. Aristolone has anticancer properties and can be studied in research for cervical cancer.
Complement System   Apoptosis  
Cancer   Digestive System Disease   Autoimmune Disease   Digestive System Inflammation  
/
HY-N8210 Homoeriodictyol
Homoeriodictyol is an orally active, bitter-tasting flavanone that can penetrate the blood-brain barrier. Homoeriodictyol enhances synaptic-related protein expression through NCOA4-mediated ferritin autophagy. Homoeriodictyol improves memory impairment in mice by inhibiting the NLRP3 inflammasome. Homoeriodictyol protects human endothelial cells from oxidative damage by activating Nrf2 and inhibiting mitochondrial dysfunction. Homoeriodictyol enhances ROS activity and induces apoptosis, exhibiting anticancer effects. Homoeriodictyol inhibits the survival and migration of androgen-resistant prostate cancer cells in vitro. Homoeriodictyol exerts antinociceptive activity in mice in vivo.
Drug Metabolite   Autophagy   Apoptosis   Reactive Oxygen Species (ROS)   Keap1-Nrf2   MMP   Caspase   PARP   MDM-2/p53  
Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis  
/
HY-D0996 LDS-751
Lds-751 is a nucleic acid stain that mainly detects DNA. Lds-751 is a nucleic acid stain that mainly detects DNA. Lds-751 has a high affinity for DNA and fluorescence is enhanced after binding, but the maximum emission wavelength is 670nm. Lds-751 and Thiazole orange can be used for the differentiation of red blood cells, platelets, reticulocytes, and nucleated cells and can be stimulated at 488nm. Studies have shown that LDS-751 binds almost exclusively to mitochondria when incubated with nucleated living cells. After nucleated Acridine Orange (HY-101879) staining and LDS-751 treatment of cells, confocal microscopy revealed almost no co-location of the cells. Staining with Rhodamine 123 (HY-D0816), a dye known to bind polarized mitochondria, was almost identical to the pattern observed with LDS-751.
DNA Stain  
/
HY-P10950A PD-L1 inhibitory peptide TFA
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
PD-1/PD-L1   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-W127502 1-Hexadecyl lysophosphatidic acid
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.
Biochemical Assay Reagents  
/
HY-113248 3-Nitro-L-tyrosine
3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
Endogenous Metabolite   Adrenergic Receptor   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P990637 NGM-621
NGM-621 is a CHO-expressed human antibody that targets Complement C3. NGM-621 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.04 kDa. The isotype control for NGM-621 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P2310 Defensin HNP-1 human
Defensin HNP-1 human is a type of human neutrophil peptide (HNPs). Defensin HNP-1 human possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human has antileishmanial activity. Defensin HNP-1 human is involved in endothelial cell dysfunction during the early development of atherosclerosis.
Bacterial   Parasite   Apoptosis   HIV   HSV   CMV   TNF Receptor   NOD-like Receptor (NLR)   DNA/RNA Synthesis   Influenza Virus  
Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-P99638 Gefurulimab
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P1823 C-Reactive Protein (CRP) (174-185)
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma.
Akt   mTOR   Caspase  
Infection   Metabolic or Endocrine Disease   Breast Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   Cardiovascular Disease  
/
HY-P10580A Vasculotide TFA
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.
Cadherin   PI3K   Claudin   Tie   Akt  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-W027544 MCA
MCA (7-Methoxycoumarin-4-acetic acid) is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities.
Fluorescent Dye  
/
HY-B0228S11 Adenosine-15N5
Adenosine-15N5 (Adenine riboside-15N5; D-Adenosine-15N5) is the 15N labled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds  
Cancer  
/
HY-136888 MeOSuc-AAPV-CMK
MeOSuc-AAPV-CMK (Elastase Inhibitor III) is an elastase inhibitor that simultaneously inhibits Cathepsin G and Proteinase 3. MeOSuc-AAPV-CMK blocks the shedding of FcgRIIIb on the surface of human neutrophils. MeOSuc-AAPV-CMK reverses the elastase-mediated reduction in proinflammatory cytokine production by immune cells, partially restores IL-1β levels in immune cell co-culture systems, and prevents elastase-mediated adiponectin cleavage.
Elastase   Cathepsin   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-153450 JBI-589
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research.
Protein Arginine Deiminase  
/
HY-W012480 DL-Tryptophan
DL-Tryptophan ((±)-Tryptophan) is an orally effective aryl hydrocarbon receptor (AhR) agonist. DL-Tryptophan reduces the expression of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, as well as liver injury markers aspartate aminotransferase and alanine aminotransferase, and alleviates hepatocyte apoptosis (apoptosis) in sepsis induced by cecal ligation and puncture. DL-Tryptophan can be used in the research of sepsis-related acute liver injury.
Endogenous Metabolite   Aryl Hydrocarbon Receptor   Interleukin Related   TNF Receptor   Apoptosis  
Liver Injury  
/
HY-P10461 Abz-Val-Ala-Asp-Nva-Arg-Asp-Arg-Gln-EDDnp
Abz-Val-Ala-Asp-Nva-Arg-Asp-Arg-Gln-EDDnp is a fluorescent FRET substrate for proteinase 3 (PR3) with selectivity over neutrophil elastase and cathepsin G. Abz-Val-Ala-Asp-Nva-Arg-Asp-Arg-Gln-EDDnp is cleaved by active PR3 to generate a detectable fluorescent signal, which is used to quantify the enzymatic activity of PR3, the concentration of free or membrane-bound PR3, and the PR3 activity on activated human neutrophils. Abz-Val-Ala-Asp-Nva-Arg-Asp-Arg-Gln-EDDnp can be applied in studies related to lung ischemia-reperfusion injury, inflammatory diseases, and other relevant conditions.
Amino Acid Derivatives   Elastase   Cathepsin  
Pulmonary Disease   Ischemia-Reperfusion Injury  
/
HY-P991127 Claseprubart
Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis.

Species: Human

Complement System  
Myasthenia gravis  
/
HY-P99520 Vilobelimab
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.

Species: Human

Complement System   SARS-CoV  
Infection   Inflammation or Immune System Disease  
/
HY-P10580 Vasculotide
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.
Tie   PI3K   Akt   Cadherin   Claudin  
Infection   Blood or Cardio-cerebrovascular Disease   Skin Inflammation  
/
HY-NP0194A C1q Protein (mouse)
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease.
Complement System  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P990025 Empasiprubart
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models.

Species: Human

Complement System  
Myasthenia gravis  
/
HY-B0228S13 Adenosine-13C10
Adenosine-13C10 (Adenine riboside-13C10; D-Adenosine-13C10) is 13C-labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Autophagy   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-P3612 CTCE-0214
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research.
CXCR  
Inflammation or Immune System Disease  
/
HY-134222A N-Acetylserine
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification.
Endogenous Metabolite   Complement System  
/
HY-P2280 TAT-P110
TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1.
Dynamin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-NP137 NP-PE (Phycoerythrin)
NP-PE (Phycoerythrin) is a complex formed by 4-Hydroxy-3-nitrophenylacetyl (NP, a hapten) with Phycoerythrin (PE, a carrier protein). NP-PE (Phycoerythrin) can induce the formation of specific immune complexes and mediate the targeted encounter and activation of B cells with antigens. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P9922 Olaratumab
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity.

Species: Human

PDGFR  
Prostate Cancer   Non-Small Cell Lung Cancer   Metastatic Pancreatic Cancer   Glioblastoma Multiforme  
/
HY-P3502 Zilucoplan
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM).
Complement System  
Musculoskeletal and Skin Disease  
/
HY-D1056A3 Lipopolysaccharides, from E. coli O26:B6
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-150097 Recombinant Human Serum Albumin(rHSA)
Recombinant Human Serum Albumin (rHSA) is a non-glycosylated monomeric plasma protein that acts as a core factor for maintaining plasma colloid osmotic pressure. Recombinant Human Serum Albumin (rHSA) possesses multiple physiological functions including carrier, metabolic regulation, detoxification, antioxidation and enzyme mimicking. Recombinant Human Serum Albumin (rHSA) not only scavenges reactive oxygen and nitrogen species via specific residues and binds a variety of endogenous and exogenous compounds to maintain redox homeostasis, but also serves as a biomarker for multiple diseases such as cancer and inflammation. Recombinant Human Serum Albumin (rHSA) broadly supports the development of implantable materials, surgical adhesives and ligand capture, and can be used for research on critical illnesses including hypovolemia, liver failure, severe sepsis and various types of trauma resuscitation.
Biochemical Assay Reagents  
Cancer   Inflammation or Immune System Disease   Liver Failure  
/
HY-125863 Glucose-6-phosphate dehydrogenase, Microorganism
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy.
Biochemical Assay Reagents  
Cancer   Glucose Metabolism  
/
HY-NP004 Cobra Venom Factor
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.).
Complement System  
Inflammation or Immune System Disease   Pulmonary Disease  
/
HY-P99050 Sutimlimab
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome.

Species: Human

Complement System  
Urologic Disease  
/
HY-W145519 Hydroxyethyl starch (MW170-230 kDa)
Hydroxyethyl starch (MW170-230 kDa) is a type of hydroxyethyl starch with a molecular weight of 170-230 kDa. A medium-molecular-weight hydroxyethyl starch (HES 200/0.62) exhibits minimal intravascular hydrolysis. The rapidly degradable medium-molecular-weight Hydroxyethyl starch 200/0.5 causes almost no coagulation disorders and improves hemorheological parameters.
Environmental Pollutants   Biochemical Assay Reagents  
Blood Disease  
/
HY-P7876 Complement Factor D/Adipsin Protein, Mouse (HEK293, His)
Complement Factor D/Adipsin Protein cleaves factor B in complex with factor C3b, activating the C3bbb complex to form the C3 convertase in the alternate pathway, analogous to C1s in the classical pathway. Complement Factor D/Adipsin Protein, Mouse (HEK293, His) is the recombinant mouse-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P7861 Complement Factor D/Adipsin Protein, Human (HEK293, His)
Complement factor D, also known as Adipsin, plays a crucial role in the alternative pathway of the complement system and when complexed with factor C3b, it cleaves factor B. This cleavage activates the C3bbb complex, converting it to the C3 convertase of the alternative pathway. Complement Factor D/Adipsin Protein, Human (HEK293, His) is the recombinant human-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P7824 Complement C8G Protein, Human (His, solution)
C8G/C8 γ is the γ subunit of the C8 protein of the complement system and is mainly localized in brain astrocytes. C8G/C8 γ is a neuroinflammation inhibitor that interacts with S1PR2 and jointly antagonizes the pro-inflammatory activity of S1P in microglia. Complement C8G Protein, Human (His, solution) is the recombinant human-derived Complement C8G protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Complement System Complement Component 8 Complement Component 8 gamma Chain

/
HY-P7861A Complement Factor D/Adipsin Protein, Human (HEK293, His, Solution)
Complement factor D, also known as Adipsin, plays a crucial role in the alternative pathway of the complement system and when complexed with factor C3b, it cleaves factor B. This cleavage activates the C3bbb complex, converting it to the C3 convertase of the alternative pathway. Complement Factor D/Adipsin Protein, Human (HEK293, His, Solution) is the recombinant human-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P78273 Complement Factor D/Adipsin Protein, Mouse (HEK293, Fc)
Complement Factor D/Adipsin Protein cleaves factor B in complex with factor C3b, activating the C3bbb complex to form the C3 convertase in the alternate pathway, analogous to C1s in the classical pathway. Complement Factor D/Adipsin Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P705312 Complement C9 Protein, Human (His, Myc)

Species: Human; Source: E. coli

Complement System Complement Component 9

/
HY-P78545 Complement Factor D/Adipsin Protein, Human (HEK293, Fc)
Complement factor D, also known as Adipsin, plays a crucial role in the alternative pathway of the complement system and when complexed with factor C3b, it cleaves factor B. This cleavage activates the C3bbb complex, converting it to the C3 convertase of the alternative pathway. Complement Factor D/Adipsin Protein, Human (HEK293, Fc) is the recombinant human-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P77898 Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, His)
Complement Factor D/Adipsin Protein is a member of the S1, or chymotrypsin, family of serine peptidases. Complement Factor D is expressed by adipose cells, plays an important role in both physiology and pathophysiology, where it plays a regulatory role in the complement system. Complement Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Complement Factor D/Adipsin protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P71726 Complement Factor D/Adipsin Protein, Rat (P.pastoris, His)
Complement Factor D/Adipsin Protein is pivotal, cleaving factor B within the factor C3b complex to activate the C3bbb complex, serving as the C3 convertase in the alternate pathway—analogous to C1s in the classical pathway. Complement Factor D/Adipsin Protein, Rat (P.pastoris, His) is the recombinant rat-derived Complement Factor D/Adipsin protein, expressed by P. pastoris , with N-6*His labeled tag.

Species: Rat; Source: P. pastoris

Complement System Complement Regulatory Proteins Factor D

/
HY-P704331 Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, Fc)
Complement Factor D/Adipsin Protein is a member of the S1, or chymotrypsin, family of serine peptidases. Complement Factor D is expressed by adipose cells, plays an important role in both physiology and pathophysiology, where it plays a regulatory role in the complement system. Complement Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Complement Factor D/Adipsin Protein, Rhesus macaque (HEK293, Fc) is the recombinant mouse-derived Complement Factor D/Adipsin protein, expressed by HEK293, with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Complement System Complement Regulatory Proteins Factor D

/
HY-P80577 C3 Antibody (YA575)
C3 Antibody (YA575) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810367 Complement factor B Antibody
Complement factor B Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Complement factor B.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P80577A C3 Antibody (YA575)(PBS only)
C3 Antibody (YA575) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81468 C1QA Antibody (YA1213)
C1QA Antibody (YA1213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C1QA.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81468A C1QA Antibody (YA1213)(PBS only)
C1QA Antibody (YA1213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C1QA.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83239 Complement factor B Antibody (YA2984)
Complement factor B Antibody (YA2984) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement factor B.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86517 Adiponectin Antibody (YA6209)
Adiponectin Antibody (YA6209) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Adiponectin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86840 Complement C5 Antibody (YA6533)
Complement C5 Antibody (YA6533) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement C5.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87384 C7 Antibody (YA7067)
C7 Antibody (YA7067) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C7.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/

Keywords

immunothrombosis | neutrophil extracellular traps | NETosis | thromboinflammation | endothelial dysfunction | platelets | complement | sepsis